

The VA ADAP has a new name – the VA Medication Assistance Program (VA MAP). We will be changing documents and other communication tools to reflect the change over the coming weeks. The Advisory Committee to VA MAP (formerly, the ADAP Advisory Committee) recently met to review the formulary. The at-a-glance **changes below are effective June 18, 2019**. Updates include medication or vaccine additions, removal of medications due to low/no utilization or outdated clinical indications, and updates for medications or vaccines that were already on the formulary. Please refer to the ADAP/VA MAP website for additional program information: <http://www.vdh.virginia.gov/disease-prevention/virginia-aids-drug-assistance-program-adap/>

Formulary Update at a Glance:

Formulary Additions

- doravirine (**Pifeltro**)
- dolutegavir DTG + lamivudine 3TC (**Dovato**)
- darunavir DRV + cobicistat COBI + tenofovir alafenamide TAF + emtricitabine FTC (**Symtuza**)
- ibalizumab-uiyk (**Trogarzo**)
- Measles, Mumps and Rubella Virus (MMR) Vaccine

Formulary Deletions

- cidofovir (Vistide)
- foscarnet (Foscavir)
- ganciclovir (Cytovene) I.V.
- indinavir (Crixivan)
- tipranavir (Aptivus)

FDA Approved Medication Update

- Human papillomavirus (HPV) Vaccine- ***Requires an ADAP Medication Exception Form***
 - Only authorized for clients with a CD4 count of 200 or more and used as **indicated in males and females up to age 45**. (Change in Age Range)